Biotech: No Downside Risk Here

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 1 June, 2017 by The TZ Newswire Staff

Biotech: No Downside Risk Here

FOCUS ON FUNDS

Biotech: No Downside Risk Here
Biotechnology stocks have suffered enough. One analyst reviews performance and valuation for the past 19 years.
By
Crystal Kim
June 1, 2017 1:10 p.m. ET

See also
- Next Article Bitcoin Price Analysis: Best Month Finishes With Potential for Bigger Highs (and Lows)
- Previous Article Trump: US will withdraw from Paris climate agreement but begin talks to re-enter
Editorial Calender

June 2017

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30

« May Jul »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 1 June, 2017 by The TZ Newswire Staff

Biotech: No Downside Risk Here

See also

Editorial Calender

Recent Tags